Overview: SCA23 PDYN Mutation TestIntroduction: The SCA23 PDYN Mutation Test detects PDYN mutations to diagnose spinocerebellar ataxia, causing movement issues. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected spinocerebellar ataxia type 23.
Other Names: SCA23 Mutation Assay, PDYN Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: SCA23 testing began in the 2000s with PDYN gene discovery. PCR methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects PDYN mutations to diagnose spinocerebellar ataxia, guides treatment, and evaluates patients with movement issues.
Test Parameters: 1. PDYN Gene Mutation
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of movement issues or neurological symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document movement issues, ataxia, or family history of spinocerebellar ataxia. Include current medications, especially those affecting coordination.
Consent: Written consent required, detailing the tests purpose, spinocerebellar ataxia implications, and risks of sample collection.
Procedural Considerations: Uses PCR to detect PDYN mutations. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for SCA23 diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Sample quality impacts specificity.
Clinical Significance: Positive PDYN mutation confirms SCA23, guiding supportive therapies or genetic counseling. Negative results may require other SCA gene testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, neurological exam, or other SCA gene tests to confirm spinocerebellar ataxia diagnosis.
Test Limitations: Specific to PDYN; other SCA types may be missed. Clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Spinocerebellar Ataxia Guidelines, 2023; Neurology, Bakalkin G, 2022.
